Verition Fund Management LLC Invests $237,000 in Fresenius Medical Care AG (NYSE:FMS)

Verition Fund Management LLC bought a new position in Fresenius Medical Care AG (NYSE:FMS) during the third quarter, according to its most recent 13F filing with the SEC. The fund bought 11,127 shares of the company’s stock, valued at approximately $237,000.

Other large investors have also recently made changes to their positions in the company. Creative Planning grew its holdings in Fresenius Medical Care by 18.9% during the 2nd quarter. Creative Planning now owns 40,140 shares of the company’s stock valued at $766,000 after purchasing an additional 6,373 shares during the last quarter. Wulff Hansen & CO. grew its holdings in Fresenius Medical Care by 1,809.0% during the 2nd quarter. Wulff Hansen & CO. now owns 343,429 shares of the company’s stock valued at $6,556,000 after purchasing an additional 325,439 shares during the last quarter. Marshall Wace LLP grew its holdings in Fresenius Medical Care by 8.5% during the 2nd quarter. Marshall Wace LLP now owns 15,363 shares of the company’s stock valued at $293,000 after purchasing an additional 1,207 shares during the last quarter. Moran Wealth Management LLC boosted its position in Fresenius Medical Care by 47.0% in the 3rd quarter. Moran Wealth Management LLC now owns 233,376 shares of the company’s stock valued at $4,971,000 after buying an additional 74,621 shares during the period. Finally, AQR Capital Management LLC purchased a new stake in Fresenius Medical Care in the 2nd quarter valued at about $197,000. 8.37% of the stock is currently owned by institutional investors.

Fresenius Medical Care Price Performance

Shares of FMS opened at $23.65 on Monday. The company has a 50 day moving average price of $21.51 and a 200-day moving average price of $20.46. Fresenius Medical Care AG has a fifty-two week low of $17.93 and a fifty-two week high of $24.31. The stock has a market capitalization of $13.88 billion, a PE ratio of 19.55, a PEG ratio of 0.96 and a beta of 0.94. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.02 and a current ratio of 1.37.

Analyst Ratings Changes

FMS has been the subject of several research reports. Bank of America raised shares of Fresenius Medical Care from an “underperform” rating to a “neutral” rating in a research report on Monday, December 2nd. Truist Financial boosted their price objective on shares of Fresenius Medical Care from $22.00 to $23.00 and gave the company a “hold” rating in a research report on Monday, October 7th. StockNews.com initiated coverage on shares of Fresenius Medical Care in a research report on Thursday, November 28th. They issued a “strong-buy” rating for the company. Finally, Berenberg Bank initiated coverage on shares of Fresenius Medical Care in a research report on Wednesday, November 6th. They issued a “buy” rating and a $25.60 price objective for the company. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, one has assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Fresenius Medical Care currently has a consensus rating of “Hold” and a consensus price target of $24.30.

Fresenius Medical Care Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.